Point72 Middle East FZE »

Denali Therapeutics shares owned by Point72 Middle East FZE

Quarter-by-quarter ownership of Denali Therapeutics (DNLI) shares owned by Point72 Middle East FZE from 13F filings

Historical chart of Point72 Middle East FZE investment in Denali Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Denali Therapeutics held by Point72 Middle East FZE consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Denali Therapeutics by Point72 Middle East FZE

Quarter filed Position value Share count Share price at filing
2023-06-30 $1.0M 36k 29.51
2023-03-31 $250k 11k 23.04
2022-12-31 $100k 3.6k 27.81

More positions owned by Point72 Middle East FZE

Spdr S&p 500 Etf Tr Tr Unit Call Option (SPY)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Spdr Dow Jones Indl Average Ut Ser 1 Call Option (DIA)
General Motors Company (GM)
Eli Lilly & Co. (LLY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Caterpillar Call Option (CAT)
UnitedHealth (UNH)
Amazon (AMZN)
Jd.com Spon Adr Cl A (JD)
Lauder Estee Cos Cl A Call Option (EL)
Target Corporation Call Option (TGT)
At&t (T)
Analog Devices Call Option (ADI)
Synopsys (SNPS)

View all positions for Point72 Middle East FZE

Top funds holding Denali Therapeutics

Baillie Gifford & Co
Vanguard Group
Wellington Management Company
Crestline Management
Baker Bros. Advisors
T. Rowe Price Associates
Flagship Ventures Management
Bank of New York Mellon
Marshall Wace
Credit Suisse
Federated Investors
Casdin Capital
Gilder, Gagnon, Howe & Co
Norges Bank Investment Management
Yiheng Capital

View all funds holding Denali Therapeutics